This PubMed record documents a pooled analysis published in the European Journal of Cancer: “Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.” The article is indexed with PMID 42372637 and DOI 10.1016/j.ejca.2026.116886. The electronic publication date listed is 12 June 2026, with an issue citation of 2026 Aug 26:244:116886.
A publisher link to Elsevier Science full-text options is provided in the PubMed entry. The record serves as a bibliographic citation pointing to a pooled analysis that addresses a clinically relevant pharmacologic question in colorectal cancer.
The paper is authored by Kenta Iguchi and a multi-national group of collaborators. The PubMed entry lists authors and their institutional affiliations across Japan, France, the Netherlands, Belgium, Germany, the USA, and Italy. Representative affiliations include:
The interdisciplinary author list includes colorectal surgeons, gastrointestinal oncologists, data scientists, and medical oncologists, indicating a collaborative effort combining clinical and quantitative expertise.
The article title indicates the study pooled randomized trials to evaluate whether anatomical tumour location within the colorectum modifies the efficacy of anti-epidermal growth factor receptor antibodies (anti-EGFR antibodies). The phrase “mapping the anatomical landscape” suggests analysis across specific subsites (for example, right colon, left colon, rectum) though exact subsite definitions are not provided in the PubMed snippet.
This question aligns with ongoing clinical interest in how tumour sidedness and subsite biology influence response to targeted agents in metastatic colorectal cancer.
PubMed lists an Elsevier link for full-text options; the DOI is included to enable direct retrieval. The Epub date is 12 June 2026 and the issue date is shown as 26 August 2026. To review trial selection, inclusion criteria, patient-level data, statistical methods, and numerical results, consult the full text at the publisher’s site or institutional subscriptions.
The provided PubMed content does not include the abstract or detailed trial-level information. Specifically, the following critical elements are not present in the source material available here:
Because these elements are absent from the PubMed snippet, it is not possible to extract or restate efficacy results or to make evidence-based clinical recommendations from this record alone.
The title signals a potentially important contribution to understanding whether tumour sidedness or anatomical subsite should influence use of anti-EGFR antibodies in colorectal cancer. However, clinicians and researchers should not change practice or interpret efficacy without reviewing the full study data. Key unknowns that determine clinical impact include the magnitude and statistical robustness of any location-specific effect, whether findings are consistent across trials, and how results interact with established molecular predictors (for example, RAS mutation status).
For researchers, the metadata confirm a pooled randomized-trial approach and a multidisciplinary author team; the full publication will be needed to evaluate methodology and reproducibility.
To assess the pooled analysis in detail, obtain the full text via the DOI link (10.1016/j.ejca.2026.116886) or through institutional access to the European Journal of Cancer. The PubMed entry provides a publisher link to Elsevier Science full-text options. After accessing the full article, readers should review trial inclusion criteria, subgroup definitions, effect estimates, and sensitivity analyses before applying findings to clinical decision-making.
Note: The present rewritten summary is limited to the bibliographic and metadata provided in the PubMed record. Methods, numerical results, and authors’ conclusions were not reported in the source text available here, and therefore are not restated or interpreted in this summary.